Insights

Measuring the return from innovation

Is R&D earning its investment?

Analysis of the performance of the top 12 life sciences companies by estimation the projected financial returns from the investment in their late stage pipelines.

For the last three years, Deloitte LLP and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines. The cohort of companies comprises the 12 publicly listed companies reporting the highest absolute research and development (R&D) spend for 2008-09. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval

Measuring the return from innovation
Did you find this useful?